Our top pick for
Biofrontera AG is a biotechnology business based in the US. Biofrontera shares (BFRA) are listed on the NASDAQ and all prices are listed in US Dollars. Biofrontera employs 155 staff and has a market cap (total outstanding shares value) of USD$171 million.
|52-week range||USD$5.2645 - USD$41.9167|
|50-day moving average||USD$8.0268|
|200-day moving average||USD$8.393|
|Wall St. target price||USD$12|
|Dividend yield||N/A (0.37%)|
|Earnings per share (TTM)||USD$-0.762|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Biofrontera stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biofrontera's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biofrontera's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 141x. In other words, Biofrontera shares trade at around 141x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Gross profit TTM||USD$26.4 million|
|Return on assets TTM||-8.44%|
|Return on equity TTM||-255.71%|
|Market capitalisation||USD$171 million|
TTM: trailing 12 months
There are currently 2,623 Biofrontera shares held short by investors – that's known as Biofrontera's "short interest". This figure is 89.6% down from 25,119 last month.
There are a few different ways that this level of interest in shorting Biofrontera shares can be evaluated.
Biofrontera's "short interest ratio" (SIR) is the quantity of Biofrontera shares currently shorted divided by the average quantity of Biofrontera shares traded daily (recently around 87433.333333333). Biofrontera's SIR currently stands at 0.03. In other words for every 100,000 Biofrontera shares traded daily on the market, roughly 30 shares are currently held short.
However Biofrontera's short interest can also be evaluated against the total number of Biofrontera shares, or, against the total number of tradable Biofrontera shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biofrontera's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Biofrontera shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Biofrontera shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biofrontera.
Find out more about how you can short Biofrontera stock.
We're not expecting Biofrontera to pay a dividend over the next 12 months.
Over the last 12 months, Biofrontera's shares have ranged in value from as little as $5.2645 up to $41.9167. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biofrontera's is 1.4649. This would suggest that Biofrontera's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.